Enzo Biochem (Enzo Biochem) Forward Dividend Yield % : 0.00% (As of Apr. 29, 2024)

View and export this data going back to 1980. Start your Free Trial

What is Enzo Biochem Forward Dividend Yield %?

As of today (2024-04-29), the Forward Annual Dividend Yield of Enzo Biochem is 0.00%.

As of today (2024-04-29), the Trailing Annual Dividend Yield of Enzo Biochem is 0.00%.

ENZ's Forward Dividend Yield % is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 1.875
* Ranked among companies with meaningful Forward Dividend Yield % only.

Enzo Biochem's Dividends per Share for the three months ended in Jan. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Enzo Biochem's Forward Dividend Yield %

For the Diagnostics & Research subindustry, Enzo Biochem's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enzo Biochem's Forward Dividend Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Enzo Biochem's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Enzo Biochem's Forward Dividend Yield % falls into.

Enzo Biochem Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Enzo Biochem (NYSE:ENZ) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Enzo Biochem Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzo Biochem (Enzo Biochem) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (NYSE:ENZ) » Definitions » Forward Dividend Yield %

Comparable Companies

PRE DRIO PSNL AWH BIOQ MDXH OCX VNRX BIAF TTOO TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

EZB:Germany

Address

527 Madison Avenue, New York, NY, USA, 10022

Website

https://www.enzo.com

Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.

Executives

Steven J Pully	director	9800 RICHMOND AVE, SUITE 700, HOUSTON TX 77042
James G. Wolf	10 percent owner	105, FLYWAY DRIVE, KIAWAH ISLAND SC 29455
Hamid Erfanian	officer: Chief Executive Officer	527 MADISON AVENUE, NEW YORK NY 10022
Patricia Eckert	officer: Interim CFO	C/O ENZO BIOCHEM, INC., 81 EXECUTIVE BLVD, SUITE 3, FARMINGDALE NY 11735
Kara Cannon	officer: Chief Operating Officer	527 MADISON AVE, NEW YORK NY 10022
Bradley Louis Radoff	director	2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
David Bench	officer: CHIEF FINANCIAL OFFICER	ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Harbert Discovery Fund, Lp	10 percent owner	HARBERT DISCOVERY FUND GP, LLC, 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Ian B. Walters	director	ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Mary Tagliaferri	director	455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Clemens Peter J Iv	10 percent owner	2383 N. BERRY'S CHAPEL RD., FRANKLIN TN 37069
Rebecca J. Fischer	director	ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Fabian Blank	10 percent owner, other: See Remarks	ROEMERSTRASSE 6, BAD BERTRICH 2M 56864
Harbert Management Corp	10 percent owner	2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Harbert Discovery Co-investment Fund I Gp, Llc	10 percent owner	2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203